DILAFOR

dilafor-logo

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. The company’s primary goal is to decrease the incidence of slow progress of labor both after induction of labor and after spontaneous onset of labor.

#SimilarOrganizations #People #Financial #Website #More

DILAFOR

Industry:
Biopharma Pharmaceutical

Founded:
2003-01-01

Address:
Solna, Stockholms Lan, Sweden

Country:
Sweden

Website Url:
http://www.dilafor.com

Total Employee:
11+

Status:
Active

Contact:
+46 70 790 02 07

Total Funding:
51 M SEK

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Euro Microsoft Exchange Online Microsoft Azure DNS Fonts.com


Similar Organizations

4d-pharma-logo

4D Pharma

4D Pharma PLC is a world leader in the development of live biotherapeutics.

novavax-logo

Novavax

Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.

Current Employees Featured

not_available_image

Per-Olov Eriksson
Per-Olov Eriksson Co-Founder & Head of Manufacturing @ Dilafor
Co-Founder & Head of Manufacturing

not_available_image

Kjell Gunnarsson
Kjell Gunnarsson Co-Founder & Head of Non-Clinical Safety ,Toxicology @ Dilafor
Co-Founder & Head of Non-Clinical Safety ,Toxicology

not_available_image

Erik Holmer
Erik Holmer Co-Founder & Head of R&D @ Dilafor
Co-Founder & Head of R&D

lena-degling-wikingsson_image

Lena Degling Wikingsson
Lena Degling Wikingsson CEO @ Dilafor
CEO
2011-02-01

Founder


not_available_image

Erik Holmer

not_available_image

Kjell Gunnarsson

not_available_image

Per-Olov Eriksson

Investors List

praktikerinvest_image

Praktikerinvest

Praktikerinvest investment in Venture Round - Dilafor

rosetta-capital_image

Rosetta Capital

Rosetta Capital investment in Venture Round - Dilafor

ostersjostiftelsen_image

Ostersjöstiftelsen

Ostersjöstiftelsen investment in Venture Round - Dilafor

Official Site Inspections

http://www.dilafor.com

  • Host name: dedserv4081.levonline.com
  • IP address: 217.70.37.81
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...

More informations about "Dilafor"

Our company - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile …See details»

Dilafor - Crunchbase Company Profile & Funding

Organization. Dilafor . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Dilafor AB is a Swedish drug development company focusing on the development of …See details»

Management - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile …See details»

Dilafor AB Company Profile | Solna, Stockholm, Sweden

Find company research, competitor information, contact details & financial data for Dilafor AB of Solna, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»

Dilafor Company Profile 2024: Valuation, Funding & Investors

Dilafor General Information Description. Producer of pharmaceutical products intended to contribute towards healthy lives for mothers, children, and families. The company's products …See details»

Dilafor Company Profile - Office Locations, Competitors ... - Craft

Dilafor is a company that develops pharmaceutical products aimed at minimizing the risk of protracted labor and associated complications. It offers Tafoxiparin, a heparan sulfate mimetic, …See details»

Dilafor - Crunchbase

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»

Dilafor - Funding, Financials, Valuation & Investors - Crunchbase

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»

Dilafor - Karolinska Development

Dilafor AB is a women’s health company based in Stockholm, Sweden, developing tafoxiparin for obstetric indications, with particular reference to protracted labor and associated …See details»

Medical need and indication - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile +46707900207 Hanna Ersson, Assistant Phone …See details»

Karolinska Development’s portfolio company Dilafor recruits

Oct 27, 2021 Dilafor has now enrolled the first patient in a Phase 2a pilot study that will investigate whether treatment with subcutaneously administered tafoxiparin can improve the …See details»

Karolinska Development’s portfolio company Dilafor has

Dec 27, 2022 STOCKHOLM, SWEDEN – December 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has enrolled …See details»

Dilafor - Contacts, Employees, Board Members, Advisors & Alumni

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»

Our Vision - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile …See details»

Karolinska Development’s portfolio company Dilafor has …

Dec 27, 2022 STOCKHOLM, SWEDEN – December 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has enrolled …See details»

Karolinska Development’s portfolio company Dilafor recruits first ...

Oct 27, 2021 Dilafor has now enrolled the first patient in a Phase 2a pilot study that will investigate whether treatment with subcutaneously administe. STOCKHOLM, SWEDEN – …See details»

How it works - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile …See details»

Karolinska Development’s portfolio company Dilafor recruits first ...

Oct 27, 2021 Dilafor has now enrolled the first patient in a Phase 2a pilot study that will investigate whether treatment with subcutaneously administered tafoxiparin can improve the …See details»

Research & Development - Dilafor AB

Dilafor AB Karolinska Institutet Science Park Fogdevreten 2A, SE-171 65 Solna Sweden For email contact, [email protected] Lena Degling Wikingsson, CEO Mobile …See details»

linkstock.net © 2022. All rights reserved